1. Home
  2. ALTO vs FULC Comparison

ALTO vs FULC Comparison

Compare ALTO & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Alto Ingredients Inc.

ALTO

Alto Ingredients Inc.

N/A

Current Price

$3.66

Market Cap

282.7M

Sector

Industrials

ML Signal

N/A

Logo Fulcrum Therapeutics Inc.

FULC

Fulcrum Therapeutics Inc.

N/A

Current Price

$3.72

Market Cap

281.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ALTO
FULC
Founded
2003
2015
Country
United States
United States
Employees
N/A
55
Industry
Major Chemicals
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
282.7M
281.1M
IPO Year
2005
2019

Fundamental Metrics

Financial Performance
Metric
ALTO
FULC
Price
$3.66
$3.72
Analyst Decision
Strong Buy
Hold
Analyst Count
3
5
Target Price
★ $8.33
$3.67
AVG Volume (30 Days)
901.9K
★ 1.4M
Earning Date
11-04-2026
11-17-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 119.51
N/A
EPS
★ 0.20
N/A
Revenue
★ $917,927,000.00
N/A
Revenue This Year
$5.33
N/A
Revenue Next Year
$1.09
N/A
P/E Ratio
$17.50
★ N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$1.40
$2.83
52 Week High
$6.11
$15.74

Technical Indicators

Market Signals
Indicator
ALTO
FULC
Relative Strength Index (RSI) 51.93 47.92
Support Level $3.46 $3.62
Resistance Level $3.79 $3.81
Average True Range (ATR) 0.15 0.07
MACD 0.02 0.00
Stochastic Oscillator 49.51 39.39

Price Performance

Historical Comparison
ALTO
FULC

About ALTO Alto Ingredients Inc.

Alto Ingredients Inc is a producer and distributor of specialty alcohols, renewable fuels and essential ingredients in the United States. The company serves five markets: Health, Home and Beauty, Food and Beverage, Essential Ingredients, and Renewable Fuels. Its customers include food and beverage companies and consumer products manufacturers and distributors. The company operates under three segments: Marketing and distribution, Pekin Campus production, and Western production.

About FULC Fulcrum Therapeutics Inc.

Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF induction and improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases.

Share on Social Networks: